1. [Potential pro-thrombotic effects of cyclooxygenase-2. inhibitors Two cases pf myocardial infarction].
- Author
-
Thuaire C, Mankoubi L, Rangé G, Roussel L, Belfaqih H, el Khayef L, Belghit A, Charaf M, and Albert F
- Subjects
- Adult, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Cyclooxygenase Inhibitors adverse effects, Factor V genetics, Female, Humans, Male, Membrane Proteins, Middle Aged, Mutation, Myocardial Infarction genetics, Prostaglandin-Endoperoxide Synthases, Tissue Plasminogen Activator therapeutic use, Treatment Outcome, Ventricular Function, Left, Cyclooxygenase Inhibitors therapeutic use, Isoenzymes antagonists & inhibitors, Myocardial Infarction drug therapy, Thrombolytic Therapy methods
- Abstract
Type 2 cyclo-oxygenase inhibitors are new anti-inflammatory drugs with better gastrointestinal tolerance than traditional non-steroidal anti-inflammatory drugs. They have no platelet anti-aggregant effects and there is still some discussion as to whether this new therapeutic class has any pro-thrombotic effects. The authors report two cases of myocardial infarction in patients considered to be at low risk treated by type 2 cyclo-oxygenase inhibitors.
- Published
- 2003